rc88
mAbexperimentalADC
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 15, 2019 (NCT04175847)
Timeline
Indications
Mechanism of action
- MesothelinImmunity, passive
MSLN immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Monomethylauristatin E
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06173037 | Phase 2 | Dec 31, 2023 | RemeGen |
| NCT05804526 | Phase 1/Phase 2 (Phase 2) | Jul 19, 2023 | RemeGen |
| NCT05508334 | Phase 1 | Sep 30, 2022 | RemeGen |
| NCT04175847 | Phase 1 | Dec 15, 2019 | RemeGen |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RemeGen | For profit | 4 | 4 | 2 | 2019 |
1 organizations
Page 1 / 1